Last reviewed · How we verify
GRT9906
GRT9906 is a selective antagonist of the P2X3 receptor that reduces pain signal transmission in sensory neurons.
GRT9906 is a selective antagonist of the P2X3 receptor that reduces pain signal transmission in sensory neurons. Used for Chronic cough, Neuropathic pain.
At a glance
| Generic name | GRT9906 |
|---|---|
| Sponsor | Grünenthal GmbH |
| Drug class | P2X3 receptor antagonist |
| Target | P2X3 |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
P2X3 receptors are ion channels expressed on nociceptive nerve fibers that mediate pain signaling when activated by ATP. By blocking P2X3, GRT9906 selectively inhibits pain transmission without affecting motor function or other sensory modalities. This mechanism makes it potentially useful for chronic pain conditions where P2X3 plays a significant role.
Approved indications
- Chronic cough
- Neuropathic pain
Common side effects
- Taste disturbance
- Headache
- Dizziness
Key clinical trials
- Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia (PHASE2)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GRT9906 Prolonged Release Tablets After Dose Escalation in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRT9906 CI brief — competitive landscape report
- GRT9906 updates RSS · CI watch RSS
- Grünenthal GmbH portfolio CI